Research platform developing boron-based reversible covalent inhibitors as novel crop protection agents. Targets chloroplast serine protease ClpP and EPSPS enzyme, offering a new mechanism of action for agricultural pest and weed management through targeted enzymatic inhibition.
This research program focuses on developing boron-containing reversible covalent inhibitors as next-generation crop protection agents. The approach centers on targeting highly conserved enzymatic pathways in plants and pathogens, specifically the Caseinolytic protease P (ClpP) complex found in chloroplasts and 5-enolpyruvoylshikimate-3-phosphate synthase (EPSPS). By leveraging boron chemistry, the platform aims to create highly specific inhibitors with novel mechanisms of action, addressing the growing need for new crop protection solutions in modern agriculture.
The technology builds on established boron-based inhibitor chemistry, including alpha-aminoboronic acids and beta-aminoboronic acids, which have demonstrated activity against bacterial ClpP across multiple species. This research extends the approach to plant-specific targets, opening new avenues for selective and effective crop protection products.
Key features:
The approach combines synthetic chemistry with biochemical validation, enabling systematic exploration of inhibitor analogs to refine molecular properties for agricultural applications.
The research is at an early-to-mid stage of development. Alpha-aminoboronic acids have already demonstrated activity against bacterial ClpP from multiple species, establishing proof-of-concept for the boron-based inhibitor approach. Current work focuses on expanding chemical diversity through analog libraries and validating activity against plant-specific ClpP. Future efforts will extend the platform to EPSPS inhibition through novel beta-aminoboronic acid chemistry, with ongoing validation against enzymatic targets to establish efficacy profiles for crop protection applications.
The University of Toronto is a comprehensive public research university with three campuses in the Toronto region and a globally scaled research enterprise. Its downtown footprint is embedded within a major academic health network and an adjacent innovation district, enabling co-located labs, clinical trials, and rapid testing with end users. Companies connect through co-op and long-duration internships, sponsored research, and access to shared core facilities and prototyping resources. Research is supported by Canada’s Tri‑Agency (NSERC, CIHR, SSHRC) and the Canada Foundation for Innovation, alongside provincial programs and industry partnerships. A dedicated technology transfer office provides IP management, licensing, and startup support through a coordinated entrepreneurship network.